Young women: Eat more fruits and vegetables now to protect your heart later
2014-03-31
(Press-News.org) MINNEAPOLIS, MN – March 29, 2014 – A diet rich in fruits and vegetables for middle-aged adults has been associated with reduced rates of coronary heart disease (CHD), especially in women. Now, research supported by the Minneapolis Heart Institute Foundation (MHIF) shows that for women, what you eat in your 20s may be just as important for your middle-aged heart. The results of the study, aimed at examining the extent to which young adults' diets are linked to cardiovascular health later in life, will be presented at the American College of Cardiology (ACC) meeting in Washington, DC on March 29 by the lead author, Michael D Miedema, MD, MPH.
In the study, researchers looked specifically at the relationship between fruit and vegetable consumption in early adulthood and the presence of calcium (plaque) build-up in the coronary arteries during middle age. They analyzed data from 2,648 participants (60.8% women) in the Coronary Artery Disease Risk in Young Adults (CARDIA) study.
The results? Young women who ate ~8 servings of fruits/vegetables per day were ~40% less likely to have calcified plaque in their arteries 20 years later, compared with young women who ate only ~3 servings of fruits/vegetables per day. The correlation is strong even after accounting for other dietary factors (like eating red meat, fish, or sugar-sweetened beverages) and traditional risk factors (like smoking and body mass index). This same benefit was not observed for young men.
"Healthy lifestyle behaviors are the foundation for the prevention of heart disease, and atherosclerotic plaque formation, the hallmark of cardiovascular disease, is a lifelong process," states Miedema. "Our results reinforce the value of establishing healthy behaviors early in adulthood and affirm that population-based approaches to reduce cardiovascular disease should include a focus on establishing a high intake of fruits and vegetables early in life." Miedema is a preventative cardiologist at the Minneapolis Heart Institute® at Abbott Northwestern Hospital and a research cardiologist with the Minneapolis Heart Institute Foundation (MHIF).
INFORMATION:
About the Minneapolis Heart Institute Foundation
The Minneapolis Heart Institute Foundation is dedicated to improving people's lives through the highest quality cardiovascular research and education.
Scientific Innovation and Research — Publishing more than 120 peer-reviewed studies each year, MHIF is a recognized research leader in the broadest range of cardiovascular medicine. Each year, cardiologists and hospitals around the world adopt MHIF protocols to save lives and improve patient care.
Education and Outreach — Research shows that modifying specific health behaviors can significantly reduce the risk of developing heart disease. Through community programs, screenings and presentations, MHIF educates people of all walks of life about heart health. The goal of the Foundation's community outreach is to increase personal awareness of risk factors and provide the tools necessary to help people pursue heart- healthy lifestyles.
About the Minneapolis Heart Institute®
The Minneapolis Heart Institute® is recognized internationally as one of the world's leading providers of heart and vascular care. This state-of-the-art facility combines the finest in personalized patient care with sophisticated technology in a unique, family-oriented environment. The Institute's programs, a number of which are conducted in conjunction with Abbott Northwestern Hospital, address the full range of heart and vascular health needs: prevention, diagnosis, treatment and rehabilitation.
ELSE PRESS RELEASES FROM THIS DATE:
Fewer deaths with self-expanding TAVR versus surgery at 1 year
2014-03-31
WASHINGTON (March 29, 2014) — Transcatheter aortic valve replacement with a self-expanding valve prosthesis for the first time has demonstrated significantly lower death rates at one year compared with conventional surgical valve replacement in high-risk patients with severe aortic stenosis, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.
Worldwide, an estimated 300,000 people have severe aortic stenosis – a faulty valve in the main artery carrying blood out of the heart – and roughly a third of them are deemed unable ...
Renal denervation shows no benefit in resistant hypertension
2014-03-31
WASHINGTON (March 29, 2014) — Renal denervation fell short of primary and secondary efficacy goals in patients with severe resistant hypertension but did meet the primary safety endpoints, according to keenly awaited data from SYMPLICITY HTN-3 presented at the American College of Cardiology's 63rd Annual Scientific Session. This pivotal trial is the largest study conducted of renal artery denervation as a treatment for resistant hypertension and the most rigorously designed, including blinding and a sham treatment in the control arm.
Hypertension increases risks for heart ...
Efforts to curb hospital readmissions take center stage
2014-03-31
WASHINGTON (March 29, 2014) — Strategies aimed at reducing the number of patients with heart failure and other cardiovascular conditions who find themselves back in the hospital after discharge were identified in six new studies presented at the American College of Cardiology's 63rd Annual Scientific Session.
One out of five Medicare patients with heart failure is readmitted to the hospital within just one month of discharge, a fact that is not only bad news for patients who would most likely prefer to avoid another hospital stay, but it also places intense economic pressures ...
Primary cardiovascular disease prevention is leaving the office
2014-03-31
MINNEAPOLIS, MN – March 30, 2014 – Early results from HeartBeat Connections, a telemedicine program supported by the Minneapolis Heart Institute Foundation (MHIF), suggest effective primary prevention for cardiovascular disease (CVD) may be achieved with a team-based approach that integrates office visits with supplemental phone coaching. HeartBeat Connections provides dietitian- and nurse-led coaching over the phone to adults at high risk for CVD, with the goal of helping to improve and control key CVD risk factors. Gretchen Benson, RD, CDE, Healthcare Systems Integration ...
Adults with inherited high cholesterol are underdiagnosed and undertreated
2014-03-31
MINNEAPOLIS, MN – March 30, 2014 – An estimated 1 in 500 people worldwide suffer from familial hypercholesterolaemia (FH), an inherited condition of extremely high cholesterol that is associated with premature heart disease and death. Despite this high prevalence, recent research funded by the Minneapolis Heart Institute Foundation (MHIF) confirms FH is underdiagnosed and undertreated. Thomas Knickelbine, MD, Preventive Cardiology Director at the Minneapolis Heart Institute at Abbott Northwestern Hospital, will present the results of research aimed at identifying just ...
Evolocumab superior to ezetimibe in lowering LDL cholesterol
2014-03-31
WASHINGTON (March 30, 2014) — Evolocumab, an injected form of a class of drugs called PCSK9 inhibitors that lower low-density lipoprotein cholesterol, also known as LDL-C or "bad cholesterol," outperformed ezetimibe with few side effects in patients unable to take statins, according to research from GAUSS-2 presented at the American College of Cardiology's 63rd Annual Scientific Session.
High LDL cholesterol is considered a major risk factor for cardiovascular disease. Statins are commonly prescribed to reduce that risk. Currently ezetimibe is one of the few options ...
Head-to-head study favors balloon-expandable transcatheter heart valves
2014-03-31
WASHINGTON (March 30, 2014) — A first-ever randomized head-to-head comparison of two devices commonly used to treat the age-related disease aortic stenosis finds balloon-expandable transcatheter valves result in more successful procedures and relieve symptoms more frequently than self-expanding valves, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.
Aortic stenosis is a condition in which a crucial valve in the heart ceases to function properly. The only cure is to replace the valve, either through open heart surgery ...
Higher risks without cardio benefits halt study of aleglitazar
2014-03-31
WASHINGTON (March 30, 2014) — The phase III AleCardio trial was ended early when patients with type 2 diabetes and recent acute coronary syndrome who were treated with aleglitazar showed higher rates of heart failure, kidney events and gastrointestinal bleeding with no offsetting cardiovascular benefits, according to data presented at the American College of Cardiology's 63rd Annual Scientific Session. All other studies with the drug have been stopped as well.
Aleglitazar sparked interest for this patient population because of its dual action on two subtypes of the PPAR ...
Darapladib falls short in chronic coronary heart disease
2014-03-31
WASHINGTON (March 30, 2014) — The novel inflammation inhibitor darapladib showed no primary-endpoint advantage over placebo in patients with chronic coronary heart disease treated with a high level of background care, although it did suggest possible benefits for more specific coronary artery-related endpoints, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session. STABILITY is the first study to test this inflammation-prevention mechanism for reducing the likelihood that plaque will become an artery-blocking clot.
Darapladib ...
Evolocumab safely drops LDL cholesterol well below statin-only baseline
2014-03-31
WASHINGTON (March 30, 2014) — The monoclonal antibody evolocumab produced highly significant reductions in low-density lipoprotein (LDL) cholesterol, the "bad cholesterol," as an add-on to statins in all treatment groups, according to data from the LAPLACE-2 study presented at the American College of Cardiology's 63rd Annual Scientific Session.
LDL cholesterol is considered a major risk factor for cardiovascular disease. "High-risk patients – such as those with clinical cardiovascular disease, high LDL cholesterol levels or diabetes – are ideally treated with high-intensity ...